alexa
Reach Us +441902928240
Primary cns Lymphoma: Analysis of Treatment by Gamma- Knife Radiosurgery and Chemotherapy in a Prospective, Observational Study | OMICS International
ISSN: 2329-6771
Journal of Integrative Oncology
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Primary cns Lymphoma: Analysis of Treatment by Gamma- Knife Radiosurgery and Chemotherapy in a Prospective, Observational Study

Andres Mauricio Alvarez*, Jose E Valerio, Sammie Coy, Alan A Stein BS and Aizik Wolf

Department of Neurological Surgery, Miami Neuroscience Center at Larkin, 6129 SW 70th St, South Miami, FL 33143, USA

Corresponding Author:
Andres Mauricio Alvarez
Department of Neurological Surgery
Miami Neuroscience Center at Larkin
6129 SW 70th St, South Miami
FL 33143, USA
Tel: (786) 871-6800
E-mail: [email protected] gmail.com

Received date: October 13, 2015; Accepted date: November 08, 2015; Published date: November 17, 2015

Citation: Alvarez AM, Valerio JE, Coy S, Alan A Stein BS, Wolf A (2015) Primary cns Lymphoma: Analysis of Treatment by Gamma- Knife Radiosurgery and Chemotherapy in a Prospective, Observational Study. J Integr Oncol 4:150. doi:10.4172/2329-6771.1000150

Copyright: © 2015 Alvarez AM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Integrative Oncology

Abstract

Objective: Colorectal cancer is the third most common cancer in the world. Quality of life is important to achieve successful treatment outcomes. The aim of this study was to assess the functional quality of life of patients with newly diagnosed colorectal cancer in order to improve our understanding as physicians of how cancer therapy influences the patients’ lives, and how we can help patients improve the quality of life on a daily basis. Method: This was a cross-sectional study conducted between January-September 2013, of a sample of 647 patients newly diagnosed with colon cancer at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Participants completed the EROTIC QLQ-CR29 questionnaire, translated into Arabic and modified for a KSA population by three oncologists. Results: In total, 40 patients were included (males, 25; females, 15). Similar findings were reported between both genders in terms of body image, postoperative complications and stomas, and these were significant issues in a substantial number of respondents. Conclusion: The quality of life of patients with colorectal cancer in KSA is poor in general, as a result of both physician- and patient-specific factors. Further studies to assess this issue are recommended. Am understanding of the difficulties that patients face should encourage physicians to consider this vital aspect of their care, positively influencing the treatment course with the aim of creating the conditions for a peaceful and optimal psychological, as well as disease, outcome.

Keywords

Primary CNS lymphoma; Radiosurgery; Gamma knife; Chemotherapy; Brain tumor; Methotrexate; Lymphoma

Introduction

Primary central nervous system lymphoma (PCNSL) is a rare cancer accounting for less than 4% of brain tumors [1]. These lesions usually present as intra-axial nodules with diffuse meningeal, periventricular, and perivascular spread being very common. The primary central nervous system extranodal high-grade malignant cells are usually large or immunoblastic cells of B-cell non-Hodgkin’s, tracing their origin back to the brain parenchyma, spinal cord, leptomeninges or eyes and are typically limited to the central nervous system (CNS) with infrequent extension outside the nervous system. Treatment modalities for patients with newly diagnosed PCNSL include radiation and/or chemotherapy [2]. While the role of radiation therapy for initial management of PCNSL is controversial, clinical trials will attempt to improve the therapeutic index of this modality. Routes of chemotherapy administration include intravenous, intraocular, intraventricular or intra-arterial. Multiple trials have outlined different methotrexatebased chemotherapy regimens and have used local techniques to improve drug delivery. A major challenge in the management of patients with PCNSL remains the delivery of aggressive treatment with preservation of neurocognitive function [3,4]. Routinely PCNSL present as single or multifocal, massive infiltrative lesions that may occur in the cortex, and penetrating deep into the white and/or gray matter. The lesions may show areas of necrosis especially in patients with immunodeficiencies. GKRS has not yet been used universally in the treatment of the PCNSL and is non-invasive, safe and shows prompt and successful results, improving the prognosis and quality of life of the patient. Like other brain tumors, one of the major contests in treatment with chemotherapeutic agents remains the delivery of therapeutic concentrations of drugs to the CNS. A study of blood–brain barrier (BBB) permeability in a rat brain tumor model established a large heterogeneity of microvascular leakage; the vasculature within and around the brain tumors has a wide range of permeability, from typical capillaries with no (BBB) leakage to a tumor vasculature that allows free entry of large molecules. Although MTX crosses the BBB, remote minus is quantifiable in the brain tissue than in the serum. High-dose MTX (>1 g/m2) has been shown to be an independent factor correlating with survival [5-8]. Thus, MTX is administered in high doses, up to 8 g/m2, in order to achieve therapeutic drug concentrations in the tumor and surrounding brain. Intravenous (IV) doses less than 1 g/m2, similar to what has been used in the treatment of other malignancies outside the brain, reach CNS concentrations generally felt not to be cytotoxic The purpose of this retrospective comparative study is to determine the effectiveness of chemotherapy using methotrexate in dose of 8 g/m2 + radiosurgery in the treatment of PCNSL.

Materials and Methods

This is a retrospective, comparative study evaluating the effect and survival rate of patient with a histological diagnosis of PCNSL treated by Methotrexate and Methotrexate + GKRS r. The study received approval through the Institutional Review Board. Strict inclusion and exclusion criteria were employed (Table 1). All patient was included if they have a pathology report of histologically confirmed PCNSL Primary inclusion criteria was subjects received Methotrexate therapy as single agent in a standard protocol dosage of 8 g/m2. This chart review evaluate clinical data and MRI images from June 1995 - May 2015.

Patients with diagnosis of PCNSL by patho-histology report of the brain lesion observed on MRI were added. The presence and size of the tumor, as well as its localization were confirmed using Brain MRI Neuro- Oncologist and Radio-Oncologist Protocol. The maximal brain tumor was measured at 1 cm and 2 cm proximal to the most distal aspect of its midline. Primary outcomes was survival rate and secondary assessed by the sensibility and decrease of the brain tumor lesion as noted on MRI.

Chart review

One experienced blinded post-doctoral fellow collected the data using red cap system from eligible patients. Those patients underwent Gamma Knife Radiosurgery and/or Methrotexate dose from institutional protocol. Patients’ inclusion criteria are outlined in Table 1.

INCLUSION CRITERIA
Patient with diagnosis of PCNSL and treated by Methotrexate
Primary CNS Lymphoma diagnosed by Neuro Histology Pathologist
EXCLUSION CRITERIA
AIDS diagnosis at time of treatment and diffuse CNS lymphomas
Patient with addiction to illegal drugs, solvents, or alcohol who are currently using or previously attempted or failed a treatment program
Patients with bacteremia, systemic infection, or infection
Patients pregnant or nursing
History of previous brain surgery or brain tumor
History of systemic Disease

Table 1: Inclusion and exclusion criteria.

Subjects was excluded on various grounds including whether or not they previously failed a surgical brain tumor removal, radiation therapy or any other chemotherapy protocol.

Statistical analysis

A power analysis by mortality rate had been evaluate by y a priori sample size calculation performed on the basis of a prior randomized study [9], which evaluated using a survival rate with a sample size of 40 patients. This study suggested a sample size of at least 31 subjects per group to detect the minimal clinically important difference in mortality rate of 1.5 standard deviations (σ) = 1.5, α = 0.05, β = 0.20). Additionally, a general estimate for detecting a one-unit change on an ordinal scale of 136 (σ = 1.0, α = 0.05, β = 0.20) resulted in the same number. The Wilcoxon rank-sum test was used for comparison of continuous data between groups. Differences between means were analyzed using two-sided t-tests. Comparison of categorical data was performed using Pearson chi-square or Fisher’s exact probability test as indicated. Ordinal ranking scores were compared using the Mantel- Haenszel test. Differences less of p=0.05 or less was reported statistical significant [10].

Results

Between June 1995 and May 2015, 128 charts was evaluated. 73 subjects in control group (Methrotezate) and 55 (Methrotexate + GKRS). Follow-up period 24 to 49 months (mean 36.9 months). There were no statistically significant differences in patient demographics or histology diagnosis (Table 2). Patients was treated using GKRS doses ranging from 12 Gy to 26 Gy (median:13.6 Gy) (Figure 1). Median survival was rate 26. 8 months in Control group and 47.6 in GKRS group from the initial diagnosis. All lesions showed a complete response after Radiosurgery when evaluated using magnetic resonance imaging 3-8 weeks (mean range 5.8 weeks).

integrative-oncology-Brain-MRI-before

Figure 1: Brain MRI before and 2 months after GK treatment.

Patient Parameters Control GKRS Group P value
Number of Patients 73 55 NA
Age (years) 58.1 ± 5.3 56.9 ± 3.3 0.685
Sex      
Male 33 (70%) 26 (56%) 0.51
Female 40 (30%) 19 (44%)  
Body-mass index (kg/m2) 24.1 ± 2.6 22.2 ± 3.1 0.39
Pre-op Diagnosis      
Tobacco use 16 22 0.25
Pre-albumin (mg/dL) 18.1 ± 1.3 19.1 ± 0.9  0.347
Albumin (g/dL) 3.4 ± 0.4 3.2 ± 0.4 0.89†
Absolute Lymphocyte Count (cells/μL) 1745 ± 468 1798 ± 401 0.20
Median Survival 26.8 months (18.3 â 29.1) 47.6 months
(28.3 â 49.1)
0.0034
Pre-op Diagnosis     0.59†

Table 2: Demographic and perioperative data.

The histologic finding in all patients was the presence of large, diffuse B-cell lymphoma. The symptoms and signs of the patients remained evidently improved within 2 - 6 weeks after GKRS and 4-10 weeks after chemotherapy alone. All treated lesions by GKRS showed complete response in magnetic resonance imaging 3 weeks to 8 weeks (mean range 6.3 weeks). There was a statistical significant difference of median survival rate chemo group alone 36.3 months from the initial diagnosis and 49.8 months in GKRS group (P=0.0034) [11,12]. The doses ranged from 12 Gy to 26 Gy (median: 13.8) 50% isodose line (range: 45-85; median 50) (Table 3). The clinical data was gathered for brain tumor lesion control, disease control, toxicity, recurrence and survival. The Kanofsky performance grade was enhanced from a preoperative average of 55% to a postoperative one of 88% in GK group. Significant factors contributing to survival greater 24 months following GKRS, were increased marginal dose (Odds ratio = 6.5, p = 0.031, 95% CI (1.4-18.57), increase in maximal dose (Odds ratio = 1.54, p = 0.012, 95% CI (1.15-2.89), and increase in pre-treatment Karnofsky score (Odds ratio = 5.13, p = 0.008, 95% CI (1.55-85.1). The side effects attributed to GKRS were minimal; none of the patients had a deterioration related to the treatment. No complications were related after procedure [13,14].

Patient Parameters Control Group Gamma Knife P Value
Tumor Size
Mean Size cm3
Median Size cm3
Size Range cm3
3.7
2.9
1.3 â 6.9
3.5
2.7
1.5 â 6.4
0.18
0.27
0.21
Presence of single or multiple lesions (%)
Single
Multiple
18%
92%
22%
78%
0.35
0.28
Tumor location
Frontal
Parietal
Temporal
Occipital
Cerebellum
10
14
19
7
6
12
11
14
7
4
0.12
0.106
0.09
0.58
0.31
Extra cranial metastasis
Yes
No
10
63
16
39
0.09
0.072
VP Shunt
Yes
No
24
49
14
41
0.068
0.35
Prior cancer 11 6 0.24
Systemic symptoms 5 3 0.587
Positive CSF cytology examination 73 51 0.187
High CSF protein level 51 43 0.14
Multiple lesions 42 29 0.0687
Values  are  given  as  mean  and  standard  deviation,  with  or  without  range  in  parentheses  and  95%confidence interval in brackets.    
†Relationship between the number of positive cases and the total number of assessed patients.    

Table 3: Brain tumor related outcomes.

Discussion

In the past 30 years, radiotherapy was the primary therapeutic modality used to manage patients with PCNSL, even though the addition of chemotherapy has not substantially enhanced their effect [4]. The side effects of intrathecal methotrexate, presumptuous preliminary comorbidities and the size of the brain lesions are risk factors to be evaluated. Combined chemo and radiotherapy, radiotherapy alone and variable chemotherapy regimens and radiation doses, as well as straight chemo and radiotherapy might prove to be more harmful than beneficial [5,6]. In fact, radiotherapy has been linked to severe neurotoxicity, predominantly amongst elder patients [7-9]. High incidence of neurotoxicity has been reported in patients receiving radiotherapy, mostly in patients older than 65 years. Moreover, up to 35% of patients present with neurologic deterioration after radiotherapy treatment, resulting in a mortality rate of 30% in 5 years. Consequently, the dilemma postured by PCNSL treatment is determination of a superior approach that would offer higher success rates while limiting adverse effects such as neurotoxicity. Importantly, not a single patient experienced any mental or memory impairment in our study, which is in partial agreement with an earlier report. Kenia, et al. [10], described a mean recurrence-free period of 24.4 months for their patients. In our observational study 16 of the patients have more than 7 brain lesions with poor clinical prognoses. 9 patients developed new lesions in other areas of the brain and repeated GKS was performed. No local recurrence was observed in any patient at a mean of 30.6 months post-GKS treatment. Our findings are in accordance with those of Kenia, and seems to be at a higher success rate that those described by others in treating patients with chemotherapy and/ or radiotherapy alone. There appeared to be a predisposition in the direction of new tumor growth in individuals who did not undergo GK treatment. We establish no suggestion of a connection between recurrence and original appearance of multiple or solitary lesions but current systemic chemotherapy would be essential. The prognosis of untreated PCNSL remains grim with median survival time being low. GKRS appears to be a valuable method for the management of primary and relapsed CNSL, since it enables exceptional local control in a shortterm management period without severe complications.

Limitation

This study has a few limitations including: (i) it is a retrospective, comparative study and (ii) lack of prospective, randomized data collection confines us in assessing the full benefits and complications of GKRS.

Conclusion

Given the well tumor control, enhanced overall survival period and lesser number of complications, GKRS can be an ideal co-adjuvant treatment option for the patients with PCNS lymphoma adding of standard Methrotexate treatment. In addition, well and prompt tumor was reported using Gamma Knife Radiosurgery allowing the immediate improve of neurological symptoms.

Acknowledgements

The authors would like to express their appreciation to Marcos E Sanchez- Gonzales MD, Phd, Juan D. Oms, MD and Sandy Sosa-Guerrero RN.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 9145
  • [From(publication date):
    December-2015 - Aug 20, 2019]
  • Breakdown by view type
  • HTML page views : 9013
  • PDF downloads : 132
Leave Your Message 24x7
Top